• DOI:10.1200/JCO.2009.25.7519
Corpus ID: 6018557

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.

@article{PujadeLauraine2010PegylatedLD,
  title={Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.},
  author={{\'E}. Pujade-Lauraine and U. Wagner and E. Aavall-Lundqvist and V. Gebski and M. Heywood and P. Vasey and B. Volgger and I. Vergote and S. Pignata and A. Ferrero and J. Sehouli and A. Lortholary and G. Kristensen and C. Jackisch and F. Joly and C. Brown and N. Le Fur and A. Du Bois},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2010},
  volume={28 20},
  pages={
          3323-9
        }
}

• É. Pujade-Lauraine, U. Wagner, +15 authors A. Du Bois
• Published 2010
• Medicine
• Journal of clinical oncology : official journal of the American Society of Clinical Oncology

PURPOSE This randomized, multicenter, phase III noninferiority trial was designed to test the efficacy and safety of the combination of pegylated liposomal doxorubicin (PLD) with carboplatin (CD) compared with standard carboplatin and paclitaxel (CP) in patients with platinum-sensitive relapsed/recurrent ovarian cancer (ROC). PATIENTS AND METHODS Patients with histologically proven ovarian cancer with recurrence more than 6 months after first- or second-line platinum and taxane-based… Expand

View on PubMed

doi.org

Save to Library

Create Alert

Cite

Launch Research Feed